Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
The Oncologist
|
April 15, 2006
Chemotherapeutic approaches for targeting cell death pathways
M Stacey Ricci, Wei-Xing Zong
Methods in Molecular Biology (Clifton, N.J.)
|
June 5, 2003
DNA footprinting
M Stacey Ricci, Wafik S El-Deiry
Blood
|
May 12, 2026
Biosimilars approved for hematologists: lessons from comparative efficacy studies and comparative analytical assessments
Thomas Herndon, Nina N Brahme, M Stacey Ricci
Cancer Research
|
April 3, 2008
Mcl-1: a gateway to TRAIL sensitization
Seok-Hyun Kim, M Stacey Ricci, Wafik S El-Deiry
JAMA
|
March 9, 2026
FDA's Regulatory Reforms to Unlock Competition and Lower Drug Costs: Breaking the Biosimilar Bottleneck
Martin A Makary, Sarah Yim, Mustafa Ünlü, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 31, 2016
FDA's Approach to Regulating Biosimilars
Steven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
Plos One
|
July 27, 2011
Dysregulated ΔNp63α inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes
Linan Ha, Roshini M Ponnamperuma, Steven Jay, et al.
Toxicology and Applied Pharmacology
|
January 5, 2010
Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs
Hans Rosenfeldt, Timothy Kropp, Kimberly Benson, et al.
Cancer Biology & Therapy
|
September 21, 2007
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4
Robyn T Sussman, M Stacey Ricci, Lori S Hart, et al.
Cancer Biology & Therapy
|
November 19, 2005
Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment
Patrick A Mayes, Latoya Campbell, M Stacey Ricci, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
The Oncologist
|
April 15, 2006
Chemotherapeutic approaches for targeting cell death pathways
M Stacey Ricci, Wei-Xing Zong
Methods in Molecular Biology (Clifton, N.J.)
|
June 5, 2003
DNA footprinting
M Stacey Ricci, Wafik S El-Deiry
Blood
|
May 12, 2026
Biosimilars approved for hematologists: lessons from comparative efficacy studies and comparative analytical assessments
Thomas Herndon, Nina N Brahme, M Stacey Ricci
Cancer Research
|
April 3, 2008
Mcl-1: a gateway to TRAIL sensitization
Seok-Hyun Kim, M Stacey Ricci, Wafik S El-Deiry
JAMA
|
March 9, 2026
FDA's Regulatory Reforms to Unlock Competition and Lower Drug Costs: Breaking the Biosimilar Bottleneck
Martin A Makary, Sarah Yim, Mustafa Ünlü, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 31, 2016
FDA's Approach to Regulating Biosimilars
Steven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
Plos One
|
July 27, 2011
Dysregulated ΔNp63α inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes
Linan Ha, Roshini M Ponnamperuma, Steven Jay, et al.
Toxicology and Applied Pharmacology
|
January 5, 2010
Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs
Hans Rosenfeldt, Timothy Kropp, Kimberly Benson, et al.
Cancer Biology & Therapy
|
September 21, 2007
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4
Robyn T Sussman, M Stacey Ricci, Lori S Hart, et al.
Cancer Biology & Therapy
|
November 19, 2005
Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment
Patrick A Mayes, Latoya Campbell, M Stacey Ricci, et al.
Page
of 2